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Abstract
Background: Metastatic melanoma is an incurable disease with an average survival of less than
one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties.
Methods: This phase II, open label, single arm study was conducted to evaluate the safety and
efficacy of 75–100 mg/m2 cisplatin combined with 300–400 mcg talabostat bid for 6, 21-day cycles.
The primary endpoint was overall response. The rate of complete responses, duration of overall
objective response, progression-free survival (PFS), and overall survival were the secondary
endpoints.
Results: Six objective partial responses were recorded in the 74 patients (8.1%) in the intention-
to-treat population. Five of these responses involved the 40 evaluable patients (12.5%). Thirty-one
percent of patients reported SAEs to the combination of talabostat and cisplatin.
Conclusion:  Acceptable tolerability was observed in the intention-to-treat population and
antitumor activity was observed in 12.5% of evaluable patients, which is not greater than historical
expectation with cisplatin alone.
Background
Therapeutic options for advanced melanoma are limited
to palliative management. No treatments have demon-
strated survival advantage once metastatic lesions
develop. Combination therapy produces the highest
response rates, but overall survival remains less than 12
months. The combination chemotherapy of cisplatin/vin-
blastine/dacarbazine produces a response rate of 40% and
a median overall survival of 9 months [1]. The regimen of
cisplatin/dacarbazine/carmustine with or without
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tamoxifen results in a 15–52% response rate and median
survival of 6.8–10.8 months [2-4]. The addition of the
biochemotherapeutic agents, interferon-alpha (IFN-α) or
interleukin-2 (IL-2), separately or in combination, pro-
duces a modest improvement in response rate, but with-
out survival benefit [5-13] and with increased toxicity.
Single-agent treatment has similarly failed to significantly
improve survival; agents that have been used include
dacarbazine [14], temozolomide [15], cisplatin [16], and
nitrosoureas [15,17].
Talabostat (valine-proline-boronic acid) together with
other amino boronic dipeptides was originally designed
as a high affinity, competitive inhibitor of the enzyme
dipeptidyl peptidase IV (DPP-IV or CD26) [18]. The com-
pound was found to stimulate hematopoiesis and antitu-
mor immune responses via cytokine upregulation [19-
21]. In addition to DPP-IV, the dipeptidyl peptidases 8
and 9 (DPP-8 and DPP-9) and fibroblast activation pro-
tein (FAP) were subsequently shown to be sensitive to
inhibition by talabostat [22,23]. Based on similarities of
protein structure and substrate specificity, DPPs-8 and -9
and FAP are classified as members of the DPP-IV-like fam-
ily of post-prolyl cleaving serine proteases [24].
DPPs-8 and -9 are cytosolic proteases and their inhibition
by talabostat has been shown to cause caspase-1 activa-
tion and IL-1β induction in macrophages, which in turn
causes upregulation of the cytokines and chemokines that
characterize the responses to talabostat, both in vitro and
in tumor-bearing mice [23]. FAP has previously been
described as a type II membrane protein with dipeptidyl
peptidase and gelatinase activity (reviewed in [24]). Stud-
ies of FAP have reported that FAP expression is induced in
fibroblasts associated with the stroma of malignant epi-
thelial tumors and healing wounds [25-27]. These reports
suggest that FAP does not appear to be expressed constitu-
tively in most healthy tissues of the adult animal;
although FAP expression in bone marrow and lymphoid
tissue from both healthy and tumor-bearing mice has
been demonstrated [22]. FAP, therefore, represents a
molecular target for talabostat in tumor stroma; but the
involvement of FAP in the antitumor effects of talabostat
in mouse tumor models is currently unclear.
The biological activities of the cytokines and chemokines
upregulated by talabostat suggest that both innate and
adaptive immunity are evoked. In animal models, tala-
bostat enhanced the production of cytokines in tumor tis-
sue and lymphoid organs, resulting in enhanced tumor-
specific T-cell-dependent [19] and T-cell-independent
[20,21] immunity. These antitumor responses were
enhanced by concomitant treatment with chemothera-
peutic agents, including cisplatin, gemcitabine, paclitaxel,
5-fluorouracil, and the monoclonal antibody rituximab
[21]. The mechanism underlying the synergistic effects is
unknown; but it may involve the exposure of tumor anti-
gens by chemotherapy-induced cellular apoptosis in
tumor models in immunocompetent mice [28].
Clinical studies have shown talabostat to be well tolerated
[29-31]. In a phase I trial in thirteen patients treated con-
comitantly with immunosuppressive chemotherapy, five
patients showed improvement in grade 3 neutropenia and
most developed elevations in serum cytokine levels [29].
A phase I trial of talabostat and rituximab in rituximab-
resistant lymphoma showed cytokine elevations in most
patients with partial response in 3 patients [31]. However,
a phase II trial of talabostat in metastatic colorectal carci-
noma reported no objective responses [32].
The cooperative or synergistic interactions observed with
cisplatin and dacarbazine are particularly relevant to the
investigation of the activity of talabostat in metastatic
melanoma. In mouse models of WEHI 164 and EL4
tumors, the combination treatment of established tumors
with talabostat and cisplatin revealed a significantly
enhanced antitumor effect compared with either agent
alone [20]. Mice rendered tumor-free following treatment
with talabostat and cisplatin were resistant to rechallenge
with tumors cells of the primary type, suggesting the
development of therapy-based immune protection. Based
on these findings, we investigated the effects of talabostat
in combination with cisplatin in patients with metastatic
melanoma.
Methods
Patient Population
Patients were eligible for inclusion if they were 18 years or
older with histologically or cytologically confirmed meta-
static melanoma, Stage IV according to the AJCC [33],
with measurable disease per Response Evaluation Criteria
in Solid Tumors (RECIST) with at least one measurable
index lesion with clearly defined margins documented by
spiral computed tomography (CT) or magnetic resonance
imaging (MRI). Color medical photograph for skin and
oral lesions or plain X-ray also were done to evaluate pres-
ence of disease. A radiated lesion was be considered an
index lesion unless there was evidence of disease progres-
sion at that site prior to first administration of study med-
ication. Additional inclusion criteria were Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus of 0, 1, or 2; and an expected survival of ≥ 12 weeks.
Patients with previously irradiated and/or resected asymp-
tomatic central nervous system (CNS) metastases were eli-
gible for the study.
Patients were excluded from study participation if they
had received more than one prior chemotherapy or
immunotherapy regimen for Stage IV melanoma, or radi-BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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ation therapy to >50% of the pelvis. Patients were also
excluded from the study if they had clinically significant
abnormalities in laboratory tests for hepatic, biliary, renal
or hematological function, per normal laboratory param-
eters. Additional factors disqualifying a potential patient
included the following: symptomatic CNS metastases
with or without significant edema; <3 weeks since prior
focused radiotherapy for brain metastases or <4 weeks
since prior whole brain radiotherapy; the need for chronic
(i.e., >7 days) oral or intravenous (IV) corticosteroid ther-
apy with >10 mg/day prednisone equivalents; any comor-
bidity or condition which, in the opinion of the
investigator, interfered with the assessments and proce-
dures of the protocol; or any malignancy within the 5
years immediately prior to the first dose of study medica-
tion with the exception of basal cell or non-metastatic
squamous cell carcinoma of the skin and carcinoma in
situ of the cervix. Patients were also excluded if they were
within 30 days of surgery, chemotherapy, radiation ther-
apy, immunotherapy, or other investigational medication
for melanoma; patients must have recovered from all of
the side effects of treatment in order to be enrolled.
Women were excluded if they were pregnant or lactating.
Women of childbearing potential and non-vasectomized
men agreed to use a barrier method of contraception dur-
ing treatment.
Study Design
This was a Phase II open-label, single-arm, multicenter
study designed to enroll up to 54 evaluable patients, with
19 evaluable patients to be enrolled into Stage 1 (safety
assessment) of the study. Upon satisfactory evaluation of
safety and initial evidence of antitumor activity, an addi-
tional 35 evaluable patients were enrolled. Patients
received combination therapy with cisplatin and Tala-
bostat.
The dose of cisplatin was 100 mg/m2 administered intra-
venously on Day 1 of each 21-day cycle for 6 cycles.
Talabostat 300 mcg was administered orally twice daily
(BID) from Days 2 through 15 of Cycle 1. In Cycle 2 or
subsequent cycles, the talabostat dose could be increased
to 400 mcg BID depending on tolerability. Patients
received study treatment in 21-day cycles for up to 6
cycles. If cisplatin was discontinued for toxicity talabostat
could be continued for subsequent cycles as single agent.
All patients were to be followed for progressive disease
(PD) and/or survival for up to 12 months following their
last dose of talabostat, unless another anti-melanoma
treatment was initiated.
The study was conducted in accordance with current US
Food and Drug Administration (FDA) regulations, good
clinical practice (GCP), the International Conference on
Harmonisation (ICH) guidelines, the version of the Dec-
laration of Helsinki current at the time of the study, and
local ethical and legal requirements. Informed consent
was signed by each patient prior to his or her participation
in the study.
Study Objectives
The primary objective was to determine objective
response rate, defined as the proportion of evaluable
patients who achieved a complete response (CR) or par-
tial response (PR) per RECIST. Objective response was
determined using an imaging technique (e.g. CT, MRI)
including all index lesions. Confirmation of response was
to be documented by repeat imaging no sooner than 4
weeks following documentation of the initial response.
Patients who did not qualify for a CR or PR were evaluated
as having either stable disease (SD) or progressive disease
(PD).
The rate of CR, duration of overall objective response, pro-
gression-free survival (PFS), and overall survival were the
secondary measures of antitumor activity. Duration of
response was defined as the time interval measured in
days between the first date on which the criteria for objec-
tive response were met and the first date on which objec-
tive progression was documented. PFS was defined as the
interval between the date of first study treatment and the
first date (plus one day) on which criteria for PD or death
were met.
Safety assessments were also a secondary objective. Occur-
rence and severity of AEs, physical examinations, weight,
vital signs, ECOG performance scores, clinical laborato-
ries (hematology, chemistry, and coagulation), and uri-
nalysis were collected. ECGs were recorded at baseline,
end of treatment and at the 30-day follow-up visit.
Statistical Analysis
Continuous variables were summarized descriptively
using mean, standard deviation (SD), median, minimum
(min), and maximum (max). Categorical variables were
summarized descriptively through the use of number and
percent. All statistical analyses were carried out using SAS®
version 8.2 running on Windows XP.
The evaluable population (N = 40) was defined as those
patients who received at least 21 days of talabostat (i.e.,
75% of the planned doses) in Cycles 1 and 2, had no more
than 7 days of vomiting in the first two cycles, and had a
post-baseline response assessment. The intention-to-treat
(ITT) population (N = 74) was defined as all patients who
received at least one dose of talabostat. The safety popula-
tion (N = 74) was defined as those patients who received
any dose of talabostat or cisplatin. In this study, these 2BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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populations were the same. The ITT population was used
in analyses of the secondary endpoints.
Results
Patient Characteristics
Initially, up to 54 evaluable patients were to be enrolled
in this study, with enrollment proceeding in 2 stages.
Stage 1 was to be completed after 19 evaluable patients
were enrolled.
However, initial evaluation of safety revealed a high une-
valuability rate related to the higher dose of cisplatin. This
cisplatin dose was reduced from 100 mg/m2 to 75 mg/m2
and additional patients were placed on trial for a total of
74 patients. Forty were evaluable for response (defined as
those patients who received at least 21 days of talabostat
in Cycles 1 and 2). In both the ITT and Evaluable popula-
tions, the median age was 58.0 years (range, 27–79). In
the ITT population, nearly all patients were white, non-
Hispanic (69/74 [93.2%]). Fifty patients (67.6%) were
male. Additional demographic and baseline clinical data
is presented in Table 1.
Efficacy
Six objective responses, all PRs, were recorded in the 74
patients in the ITT Population for a response rate of 8.1%
Table 1: Baseline demographic data and disease characteristics of enrolled patients.
ITT Population
(N = 74)
Evaluable Population
(N = 40)
Age, yrs
Median (range) 58.0 (27–79) 58.0 (32–79)
Mean (SD) 57.6 (12.79) 58.9 (13.08)
Race, n (%)
White, Non-Hispanic 69 (93.2) 39 (97.5)
Black, Non-Hispanic 2 (2.7) 1 (2.5)
Hispanic 2 (2.7) 0
Asian or Pacific Islander 1 (1.4) 0
Gender, n (%)
Male 50 (67.6) 28 (70.0)
Female 24 (32.4) 12 (30.0)
Tobacco use, n (%)
Never 32 (43.2) 14 (35.0)
Past 26 (35.1) 17 (42.5)
Current 16 (21.6) 9 (22.5)
ECOG performance status, n (%)
0 32 (43.2) 20 (50.0)
1 42 (56.8) 20 (50.0)
Time since initial melanoma diagnosis, months
Median (range) 28.0 (1–420) 30.5 (3–225)
Mean (SD) 50.1 (66.28) 45.5 (45.43)
Time since first diagnosis of Stage IV melanoma, months
Median (range) 4.0 (0–89) 5.0 (0–30)
Mean (SD) 9.3 (15.66) 7.5 (7.61)
Stage at original diagnosis, n (%)
Stage 0 1 (1.4) 0
Stage I 10 (13.5) 3 (7.5)
Stage II 16 (21.6) 8 (20.0)
Stage III 26 (35.1) 15 (37.5)
Stage IV 18 (24.3) 11 (27.5)
Stage unknown 3 (4.1) 3 (7.5)
Histologic subtype, n (%)
Superficial spreading melanoma 17 (23.0) 7 (17.5)
Nodular melanoma 30 (40.5) 20 (50.0)
Acral lentiginous melanoma 3 (4.1) 0
Other 24 (32.4) 13 (32.5)
Current M classification by sites of metastasesa, n (%)
M1a: Distant skin, subcutaneous, or nodal metastases 7 (9.5) 4 (10.0)
M1b: Lung metastases 13 (17.6) 7 (17.5)
M1c: All other visceral metastases 54 (73.0) 29 (72.5)
ITT = intention-to-treat; SD = standard deviation; ECOG = Eastern Cooperative Oncology Group
a Per 2002 AJCC. Baseline LDH levels were used in this classification.BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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(6/74). Five of these responses were in the evaluable pop-
ulation, for a response rate of 12.5% (5/40). Response
assessments based on RECIST criteria and are summarized
in Table 2.
The most common assessment of SD was documented in
25/40 (62.5%) of evaluable patients at cycle 3, day 1 and
13/40 (32.5%) at Cycle 5, Day 1. The duration of stable
disease in 12 evaluable patients was not maintained out
to cycle 5. For the patients who responded, the duration
of the response ranged from 62 to 287 days. Table 3
presents disease assessments, prior treatments, and the
response to talabostat for all patients with objective over-
all responses.
The estimate of median PFS using the Kaplan-Meier sur-
vival analysis algorithm for the ITT population was 92.0
days based on the investigator assessment using RECIST.
Table 4 presents the overall median PFS estimate. The esti-
mates of PFS was suggested to be greater for patients with
a M1b classification and escalated dose of talabostat.
For the ITT Population, the estimate of median overall
survival using the Kaplan-Meier algorithm was 230.0
days, regardless of whether patients starting a new anti-
melanoma therapy were censored. Table 5 presents
median survival estimates for the ITT Population overall,
and by M classification, prior chemotherapy treatment,
dose escalation with talabostat, or initial cisplatin dose.
The overall survival estimates were greater for patients
who did not receive prior chemotherapy (340.0 vs. 165.0
days) and for those who dose-escalated with talabostat
(330.0 vs. 139.0 days). The initial cisplatin dose level did
not significantly impact overall survival.
Safety
All enrolled patients who received any talabostat or cispl-
atin were included in the safety population (N = 74). The
majority of adverse events (AEs) (821/1071 [76.7%])
occurred during the first 3 cycles of treatment. Forty-two
patients (42/74 [56.8%]) experienced grade 3 or grade 4
AEs, 23/74 (31.1%) patients reported SAEs, and 14/74
(18.9%) patients discontinued talabostat due to an AE. A
summary of AEs by cycle and overall is presented in Table
6. AEs experienced by ≥ 3 patients (4.1%) in the Safety
Population are listed in Table 7 by system organ class,
with the preferred terms listed in decreasing frequency.
Ten patients (10/74 [13.5%]) had AEs which were consid-
ered by the investigator as definitely related to talabostat.
These AEs included 7 patients with events of edema
(including peripheral, localized, facial, and periorbital
edema, fluid retention, and edema NOS), two patients
with nausea, and one incident each of rigors, performance
status decreased, weight increased, myalgia, genital
edema, pruritis, or peripheral cyanosis. With the excep-
tion of performance status decrease, which occurred dur-
ing the extended treatment cycles (>cycle 6), these events
occurred exclusively in cycles 1 and/or 2. AEs experienced
by ≥ 3 patients by dose level of talabostat are presented in
Table 8. The percentage of patients experiencing AEs were
similar between dose groups in most body system organ
classes.
Over a third of the patients (27/74 [36.5%]) had AEs con-
sidered by the investigator as definitely related to cispla-
tin. The majority of these events involved the
hematopoietic system (15 patients; 11 with neutropenia,
febrile neutropenia, and/or neutrophil count decreased)
Table 2: Overall objective response rate of patients at cycle 3 and maintained to cycle 5 or end of treatment.
Timepoint ITT Population Evaluable Population
Overall response to treatmenta (N = 74) (N = 40)
Cycle 3, Day 1
CR 00
PR 3 (4.1)b 3 (7.5)
SD 34 (45.9) 25 (62.5)
Cycle 5, Day 1
CR 00
PR 3 (4.1) 3 (7.5)
SD 16 (21.6) 13 (32.5)
End of treatment or early termination
CR 00
PR 2 (2.7) 1 (2.5)
SD 10 (13.5) 7 (17.5)
ITT = intention-to-treat; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease
a Response is based on the investigator's assessment using RECIST.
b N (%).BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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or gastrointestinal disorders (14 patients; 11 with vomit-
ing NOS). Of the 4 most common AEs experienced by
patients in this study, the majority were considered possi-
bly, probably, or definitely related to cisplatin (43/44
events of nausea, 35/38 vomiting, 32/37 fatigue, and 27/
29 events of anemia). A summary of AEs by severity and
by relationship to talabostat or cisplatin is presented in
Table 9 by cycle and overall.
The number and percent of patients with AEs were also
analyzed by the initial cisplatin dose the patient received
(100 mg/m2 or 75 mg/m2). Patients whose initial cisplatin
dose was 75 mg/m2 experienced fewer AEs in the hemat-
opoietic system (18/39 [46.2%]) as well as in the organ
system category of AE's (13/39 [33.3%]), compared to
those who received the 100 mg/m2 dose (23/35 [65.7%]
and 19/35 [54.3%], respectively).
Table 3: Objective response to talabostat.
Age/Sex
(Patient No.)
M classification 
at enrollmenta
Metastatic sites at 
enrollment
Prior Tx for
Stage IV diseaseb
Best response 
to prior Tx
Response to 
talabostat
Duration of 
Response (days)
54/F
(01-003)
M1b Skin, lung Tumor peptide 
heat shock 
(Vitespen)
PD PR 151
46/M
(04-002)
M1b Lung Sargramostim PD PR 62
63/M
(04-003)
M1b Lung None NA PR 287
61/F
(06-001)
M1c Subcutaneous tissue, 
stomach, lymph 
node(s), visceral
Temozolomide, 
thalidomide
SD PR Unknownc
53/M
(09-014)
M1c Regional lymph 
node(s), liver
None NA PR 176
58/F
(12-003)
M1c Lymph nodes beyond 
regional, lung, 
abdominal wall
None NA PR 141
Tx = treatment; PD = progressive disease; PR = partial response; NA = not applicable; SD = stable disease
a M1a: Distant skin, subcutaneous, or nodal metastases; M1b: Lung metastases; M1c: all other visceral metastases. Baseline LDH levels were also 
used in this classification.
b Includes chemotherapy and/or immunotherapy.
c The patient was lost to follow-up.
Table 4: Progression free survival
----------Time to PD or Death (days)a----------
Median (95% CI), days
Overall PFS (N = 74)b 92.0 (79.0, 126.0)
Exploratory Analyses
PFS by:
M classification
M1a (n = 7) 85.0 (40.0, 270.0)
M1b (n = 13) 135.0 (103.0, 205.0)
M1c (n = 54) 85.0 (68.0, 110.0)
Prior chemotherapy
With (n = 40) 89.0 (78.0, 143.0)
Without (n = 34) 97.0 (42.0, 180.0)
Dose escalation of talabostat
With (n = 44) 135.0 (89.0, 170.0)
Without (n = 30) 79.0 (42.0, 109.0)
Initial cisplatin dose
100 mg/m2 (n = 35) 80.0 (44.0, 103.0)
75 mg/m2 (n = 39) 126.0 (85.0, 169.0)
PD = progressive disease; PFS = progression-free survival; CI = confidence interval
a Response is based on the investigator's assessment.
b ITT population.BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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Twenty-three patients (23/74 [31.1%]) reported SAEs; 15
of these patients were receiving talabostat at 300 mcg BID
at the time of their event and 8 had dose-escalated to 400
mcg BID. The incidence of SAEs was relatively constant
over the 6 cycles of treatment, ranging from 5.3 to 13.1%
of patients in a given cycle experiencing an SAE. There
were no SAEs reported in the extended treatment phase of
the study (> Cycle 6).
Eleven SAEs were reported in more than one patient:
dehydration was reported in 6 patients; vomiting, dizzi-
ness, acute renal failure, dyspnea, and hypotension NOS
were each reported in 3 patients; and 2 patients each expe-
rienced nausea, fatigue, pain NOS, renal failure NOS, or
orthostatic hypotension. One patient experienced SAEs of
peripheral edema, facial edema, and peripheral cyanosis
that were considered definitely related to talabostat. A sec-
Table 5: Overall survival
------------------------------Time to Death (days)------------------------------
Analysis with censoring of patients who began 
a new therapya
Analysis without censoring of patients who 
began a new therapyb
Median (95% CI), daysc Median (95% CI), daysc
Overall Survival (N = 74) 230.0 (143.0, 401.0) 230.0 (148.0, 330.0)
Exploratory Analyses
Overall survival by:
M classification
M1a (n = 7) NE (270.0, NE) 340.0 (270.0, NE)
M1b (n = 13) NE (230.0, NE) NE
M1c (n = 54) 148.0 (116.0, 297.0) 148.0 (117.0, 239.0)
Prior chemotherapy
With (n = 40) 165.0 (118.0, 297.0) 165.0 (143.0, 297.0)
Without (n = 34) 401.0 (138.0, NE) 340.0 (139.0, NE)
Dose escalation of talabostat
With (n = 44) 330.0 (153.0, NE) 330.0 (165.0, NE)
Without (n = 30) 139.0 (81.0, 270.0) 139.0 (81.0, 230.0)
Initial cisplatin dose
100 mg/m2 (n = 35) 230.0 (109.0, NE) 239.0 (116.0, 401.0)
75 mg/m2 (n = 39) 209.0 (148.0, NE) 209.0 (148.0, 340.0)
CI = confidence interval; NE = non-estimable
a Patients not dying had their survival time censored on the last date of known contact. Patients who began another anti-melanoma therapy were 
censored on the start date of the new anti-melanoma treatment.
b Patients not dying had their survival time censored on the last date of known contact. Patients who began another anti-melanoma therapy were 
not censored because of the new therapy.
c In many cases, there was insufficient information to calculate the median or the upper limit for the CI for these data.
d ITT population.
Table 6: Adverse events.
Cycle 1
(n = 74)a
Cycle 2
(n = 61)
Cycle 3
(n = 38)
Cycle 4
(n = 32)
Cycle 5
(n = 19)
Cycle 6
(n = 18)
>Cycle 6
(n = 15)
Overall
(N = 74)
Number of AEs 448 245 128 79 38 28 105 1071
No AEs 7 (9.5)b 7 (11.5) 7 (18.4) 11 (34.4) 7 (36.8) 6 (33.3) 1 (6.7) 1 (1.4)
≥ 1AE 67 (90.5) 54 (88.5) 31 (81.6) 21 (65.6) 12 (63.2) 12 (66.7) 14 (93.3) 73 (98.6)
≥ 1Possibly, probably, or definitely talabostat-related 
AEs
50 (67.6) 37 (60.7) 14 (36.8) 11 (34.4) 10 (52.6) 10 (55.6) 9 (60.0) 59 (79.7)
≥ 1Grade 3 or 4 AEs 15 (20.3) 11 (18.0) 10 (26.3) 6 (18.8) 4 (21.1) 2 (11.1) 3 (20.0) 42 (56.8)
Discontinued talabostat due to ≥ 1 AE 8 (10.8) 1 (1.6) 0 1 (3.1) 1 (5.3) 0 3 (20.0) 14 (18.9)
≥ 1SAE 9 (12.2) 8 (13.1) 3 (7.9) 2 (6.3) 1 (5.3) 1 (5.6) 0 23 (31.1)
Deaths 10 (13.5) 12 (19.7) 6 (15.8) 5 (15.6) 1 (5.3) 1 (5.6) 4 (26.7) 39 (52.7)
AE = adverse event; SAE = serious adverse event
a Safety population, n = 74.
b N (%) of patients.BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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ond patient experienced SAEs of anasarca, dehydration,
and renal failure NOS, all considered probably related to
talabostat. Both patients recovered from the events.
The incidence of specific hematologic events was analyzed
(Table 6). Few patients experienced AEs of grade 4 neutro-
penia, febrile neutropenia, grade 3 or grade 4 anemia, or
infections requiring hospitalization. Grade 3/4 neutrope-
nia and thrombocytopenia was observed in 18.9% and
24.3% of patients, respectively. No trends for an effect of
talabostat on these hematologic parameters were evident
in this study.
Overall, there were a total of 39 (39/74 [52.7%]) deaths
in this study, the majority of which (36/39) were due to
PD. Eleven patients died within 30 days of receiving tala-
bostat: 5 patients died due to PD, melanoma was the
cause of death for 3 additional patients, one patient had a
myocardial infarction, and 2 patients died of organ failure
(end organ failure and renal failure). Hepatic/renal failure
also contributed to the death of one patient with meta-
static melanoma. The death from renal failure was consid-
ered possibly related to both talabostat and cisplatin, and
the myocardial infarction was considered unlikely related
to talabostat but possibly related to cisplatin. The other
deaths were considered not related or unlikely to be
related to the study medications.
Eighteen patients (18/74 [24.3%]) experienced ≥ 1 AE
that led to discontinuation of study medication. Fourteen
of these patients (14/74 [18.9%]) discontinued talabostat
(6 patients discontinued talabostat only and 8 patients
discontinued both talabostat and cisplatin); 4 patients
discontinued cisplatin, but continued receiving tala-
bostat.
Discussion
Metastatic melanoma carries a grave prognosis, with over-
all survival of less than 12 months despite significant
efforts to develop novel therapeutic agents. Talabostat is
an orally available dipeptidyl peptidase inhibitor with
immunogenic properties that has demonstrated therapeu-
tic effects in a mouse model of melanoma [28].
The results from this phase II trial of talabostat and cispl-
atin in metastatic melanoma failed to show significant
improvement over currently available treatments. Of 74
patients in the ITT population, those who received a single
dose of talabostat, six objective responses, all PRs, were
recorded for a response rate of 8.1% (6/74). Five of these
responses were also in the evaluable population (those
who did not progress within the first 21 days of treat-
ment), yielding a response rate of 12.5% (5/40) for this
population. The duration of the response ranged from 62
to 287 days. By the end of treatment or extended treat-
ment, however, most evaluable patients were reported to
have PD.
The estimate of median PFS using the Kaplan-Meier sur-
vival analysis algorithm for the ITT population was 92.0
days, based on the investigator assessment using RECIST
criteria. The estimates of PFS appeared greater for patients
Table 7: Adverse events in ≥ 3 patients overall by system organ class and preferred term events.
System Organ Classa
Preferred Term
Cycle 1
(n = 74)b
Cycle 2
(n = 61)
Cycle 3
(n = 38)
Cycle 4
(n = 32)
Cycle 5
(n = 19)
Cycle 6
(n = 18)
>Cycle 6
(n = 15)
Overall
(N = 74)
Blood and Lymphatic System Disorders 24 (32.4)c 17 (27.9) 11 (28.9) 9 (28.1) 5 (26.3) 3 (16.7) 4 (26.7) 41 (55.4)
Anaemiad 14 (18.9) 9 (14.8) 6 (15.8) 3 (9.4) 1 (5.3) 1 (5.6) 2 (13.3) 29 (39.2)
Thrombocytopeniae 8 (10.8) 3 (4.9) 3 (7.9) 6 (18.8) 5 (26.3) 2 (11.1) 4 (26.7) 18 (24.3)
Neutropeniaf 8 (10.8) 3 (4.9) 6 (15.8) 1 (3.1) 3 (15.8) 0 2 (13.3) 14 (18.9)
Leukopeniag 1 (1.4) 2 (3.3) 3 (7.9) 1 (3.1) 1 (5.3) 0 1 (6.7) 7 (9.5)
Cardiac Disorders 2 (2.7) 2 (3.3) 0 0 1 (5.3) 0 0 5 (6.8)
Palpitations 2 (2.7) 0 0 0 1 (5.3) 0 0 3 (4.1)
Ear and Labyrinth Disorders 11 (14.9) 4 (6.6) 5 (13.2) 0 1 (5.3) 0 1 (6.7) 19 (25.7)
Tinnitus 8 (10.8) 3 (4.9) 4 (10.5) 0 0 0 0 13 (17.6)
Hypoacusis 3 (4.1) 2 (3.3) 2 (5.3) 0 0 0 0 5 (6.8)
Eye Disorders 4 (5.4) 3 (4.9) 5 (13.2) 1 (3.1) 2 (10.5) 0 3 (20.0) 13 (17.6)
Vision blurred 0 2 (3.3) 1 (2.6) 1 (3.1) 1 (5.3) 0 1 (6.7) 6 (8.1)
a System organ classes are presented alphabetically and preferred terms are listed by decreasing frequency and ordered by the "Overall" column. A 
patient with multiple occurrences of an AE is counted only once for the AE category. A patient who reported ≥ 2 AEs with different preferred 
terms within the same system organ class was counted only once in the system organ class total. AEs that do not meet frequency criteria for 
inclusion in the table are included in the system organ class totals.
b Safety population, n = 74.
c N (%) of patients.
d Includes terms: anaemia, anaemia NOS, red blood cell count decreased, and haemoglobin decreased.
e Includes terms: thrombocytopenia and platelet count decreased
f Includes terms: neutropenia and neutrophil count decreased.
g Includes terms: leukopenia and leukopenia NOS.BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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with an M1b classification and escalated dose of tala-
bostat. The estimate of median overall survival was 230.0
days, regardless of whether patients starting a new anti-
melanoma treatment were censored. Overall survival esti-
mates were greater for patients who dose-escalated and for
patients with no prior chemotherapy.
In this population of patients with advanced disease, 56/
74 (75.7%) patients were unable to complete 6 cycles (18
weeks) of talabostat, primarily due to PD. There were 15
patients who completed 6 cycles of talabostat and contin-
ued to receive additional cycles of talabostat.
Overall, the combination of talabostat and cisplatin was
well tolerated compared to historical data using cisplatin
alone. The most frequent AEs were nausea, vomiting,
fatigue, anemia, edema, and constipation. Most of these
events were considered related to cisplatin. The majority
of patients experienced either a grade 2 or a grade 3 AE as
their most severe event. The percentages of patients expe-
riencing AEs and the types of AEs were similar between the
groups who did and did not dose-escalate. This safety pro-
file is consistent with phase 1 studies conducted in 120
healthy male volunteers, in which talabostat was well tol-
erated at single daily doses up to 2400 μg and when
administered as a single dose for seven days at doses up to
1800 μg [30]. However, given the toxicity profile that we
observed to cisplatin and a slightly higher early death rate
than expected related to progressive disease, further safety
assessment is necessary.
Conclusion
In conclusion, despite promising preclinical evidence,
combination treatment with talabostat and cisplatin did
not significantly affect disease progression in this study.
Antitumor activity was observed in 5/40 (12.5%) of eval-
Table 8: Adverse events in ≥ 3 patients by talabostat dose level.
----Talabostat Dose BID---
System Organ Classa 300 mcg 400 mcg Overall
Preferred term (n = 74)b (n = 44) (N = 74)
Blood and Lymphatic System Disorders 32 (43.2)c 19 (43.2) 41 (55.4)
Anaemiad 20 (27.0) 11 (25.0) 29 (39.2)
Thrombocytopeniae 13 (17.6) 8 (18.2) 18 (24.3)
Neutropeniaf 12 (16.2) 5 (11.4) 14 (18.9)
Leukopeniag 4 (5.4) 4 (9.1) 7 (9.5)
Cardiac Disorders 2 (2.7) 3 (6.8) 5 (6.8)
Palpitations 2 (2.7) 1 (2.3) 3 (4.1)
Ear and Labyrinth Disorders 15 (20.3) 5 (11.4) 19 (25.7)
Tinnitus 10 (13.5) 4 (9.1) 13 (17.6)
Hypoacusis 4 (5.4) 1 (2.3) 5 (6.8)
Eye Disorders 9 (12.2) 7 (15.9) 13 (17.6)
Vision blurred 2 (2.7) 4 (9.1) 6 (8.1)
Gastrointestinal Disorders 54 (73.0) 21 (47.7) 58 (78.4)
Nausea 38 (51.4) 11 (25.0) 44 (59.5)
Vomiting NOS 31 (41.9) 10 (22.7) 38 (51.4)
Constipation 22 (29.7) 7 (15.9) 25 (33.8)
Diarrhoea NOS 9 (12.2) 5 (11.4) 13 (17.6)
Abdominal pain NOS 3 (4.1) 4 (9.1) 7 (9.5)
Dyspepsia 2 (2.7) 3 (6.8) 5 (6.8)
Stomatitis 1 (1.4) 2 (4.5) 3 (4.1)
BID = twice daily
a System organ classes are presented alphabetically and preferred terms are listed by decreasing frequency and ordered by the "Overall" column. A 
patient with multiple occurrences of an AE is counted only once for the AE category. A patient who reported ≥ 2 AEs with different preferred 
terms within the same system organ class was counted only once in the system organ class total. AEs that do not meet frequency criteria for 
inclusion in the table are included in the system organ class totals.
b Safety population, n = 74.
c N (%) of patients.
d Includes terms: anaemia, anaemia NOS, red blood cell count decreased, and haemoglobin decreased.
e Includes terms: thrombocytopenia and platelet count decreased.
f Includes terms: neutropenia and neutrophil count decreased.
g Includes terms: leukopenia and leukopenia NOS.BMC Cancer 2009, 9:263 http://www.biomedcentral.com/1471-2407/9/263
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uable patients, suggesting the possibility of clinical bene-
fit in a subset of melanoma patients. Based on its low
toxicity profile, additional research may be warranted to
investigate the potentiating antitumor effects of talabostat
on other chemotherapeutic and biologic agents, perhaps
in patients with earlier stage disease.
It is unclear if the antitumor activity of talabostat as seen
in pre-clinical models involves the induction of immuno-
logically active cytokines and chemokines thereby mediat-
ing an immune response or inhibition of tissue
remodeling via FAP. No clinical assessment of talabostat
in FAP-expressive tumors has as yet been performed.
Although clinical development of talabostat has focused
on the immune-mediated activity, further assessment of
talabostat in patients with FAP-expressive cancers may be
worthwhile.
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